LAS VEGAS--(BUSINESS WIRE)-- <\/p>\n
Three-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical demonstrate 70.7 percent primary patency in the superficial femoral artery (SFA) at 36 months for patients treated with the paclitaxel-eluting stent. This compares to 49.1 percent patency for patients with percutaneous transluminal angioplasty and provisional bare metal stent placement in the 479-patient study. <\/p>\n
In addition, the paclitaxel coating was shown to reduce the restenosis rate by 53 percent in a head-to-head comparison of provisional paclitaxel-eluting versus bare metal stent placement. <\/p>\n
Michael Dake, M.D., professor in the Department of Cardiothoracic Surgery at Stanford University Medical School and medical director of the Cath\/Angio Laboratories at Stanford University Medical Center, Palo Alto, California, presented the study findings yesterday at the Vascular InterVentional Advances (VIVA) 2012 conference in Las Vegas, Nev. <\/p>\n
These data, from the largest clinical study ever conducted on peripheral stenting, clearly show a sustained drug effect for paclitaxel-eluting stents versus bare metal stents after three years, said Rob Lyles, vice president and global leader of Cook Medicals Peripheral Intervention clinical division. We are proud to have pioneered this important technology. <\/p>\n
Zilver PTX is neither approved by U.S. Food and Drug Administration nor available for sale in the United States. Dr. Dake, the global principal investigator for the Zilver PTX trial, is a paid consultant to Cook Medical regarding the research and development of medical devices. <\/p>\n
About Cook Medical <\/p>\n
A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit http:\/\/www.cookmedical.com<\/a>. Follow Cook Medical on Twitter and LinkedIn. <\/p>\n<\/p>\n Read the original post: LAS VEGAS--(BUSINESS WIRE)-- Three-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical demonstrate 70.7 percent primary patency in the superficial femoral artery (SFA) at 36 months for patients treated with the paclitaxel-eluting stent. This compares to 49.1 percent patency for patients with percutaneous transluminal angioplasty and provisional bare metal stent placement in the 479-patient study. In addition, the paclitaxel coating was shown to reduce the restenosis rate by 53 percent in a head-to-head comparison of provisional paclitaxel-eluting versus bare metal stent placement. Continue reading
\nCook Medical\u2019s Zilver\u00ae PTX\u00ae Trial Shows Sustained Patency after Three Years<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"